Background: During the last four decades the prognosis of childhood acute myeloid leukemia (AML) has been substantially improved due to an increase in complete remission (CR) rates, event-free survival (EFS) and reduced early mortality. The relapsed AML still remains a therapeutic challenge. Aim: To report the AML treatment results of the Bulgarian pediatric oncohematological centers.
Acute myeloid leukemia (AML) comprises a heterogeneous group of closely related clonal disorders of the hematopoietic cells and constitutes nearly 5% of all malignancies and approximately 18% of the childhood acute leukemia cases. 1, 2 Recent advances in the diagnosis and treatment of AML have led to a signifi cant improvement of the prognosis worldwide. [3] [4] [5] [6] [7] With modern chemotherapeutic protocols a complete clinical and hematological remission (CR) can be induced in about 80% -90% of the children with newly diagnosed AML, and in nearly 30% to 70% of the cases the remission is sustained. However, severe bleeding, leukostasis, infectious complications or a refractory disease are major causes of remission-induction failure and early death in about 10% to 20% of patients. Moreover, 30% to 40% of the children will experience a relapse, even if CR is achieved. That is why the prognosis of patients with primary-refractory or relapsed AML still remains poor, with a 5-year overall survival (OS) rates of only about 25-35%, which turns their treatment into a challenge. [8] [9] [10] 
AIM
Since 2003, a Berlin-Frankfurt-Muenster (BFM) -type protocol has been approved for the treatment of children and adolescents with primary AML in all the 3 pediatric oncohematological centers in Bulgaria, with the aim of improving the prognosis in these patients. This article reports the results of such an approach for the period 2003-2016.
MATERIALS AND METHODS
Patients between 0 and 20 years old, diagnosed with AML according to the French-American-British (FAB) or WHO classifi cation were included. Cases with Down syndrome or AML as secondary malignancy, or MDS with <20% blasts, were excluded. Risk group (high risk -HR and standard risk -SR) assignment is according to the treatment protocol used.
STATISTICAL ANALYSIS
In this clinico-epidemiologic, retrospective descriptive analysis the quantitative variables were indicated in absolute values, percentage or as an arithmetic mean. For OS, deaths from any cause were considered an event. Event free survival (EFS) was calculated from the date of diagnosis to the last follow-up or fi rst event (failure to achieve remission, resistant leukemia, relapse or death of any cause). Survival probabilities were calculated using the Kaplan-Meyer method, with the level of signifi cance set at p<0.05. Graphical analysis was applied for descriptive purposes.
RESULTS
For the thirteen-year period, a total of 106 AML cases from all the three institutional databases were collected. Of these, 97 (44 girls and 53 boys) were included in this analysis. Median age at diagnosis was 10.2 years (0.2 -20 yrs). The diagnosis was based on the examination of bone marrow smears by the local hematologists and cytogenetic and fl ow cytometry analyses -at the local and/or referent pathology departments. Morphological FAB phenotype was documented in 74.2% of the cases, with M2 being the most common (23.7%), and molecular -or cytogenetic results were found in 34%. In 66% of all cases there was no data from either molecular or cytogenetic studies and in 25.8% -the FAB subtype was missing, most of these children being diagnosed and treated before 2008. Detailed demographic and disease characteristics of the patients are given in Table 1 . from sibling donor and 4 from matched unrelated donor (MUD). One child with refractory AML was MUD-transplanted with no CR1 achieved. For the whole group, the overall survival for the 13-year period was 54.6% (Fig. 1) . The EFS was 49% and varied signifi cantly for the different risk groups (Fig. 2 and Table 2 ).
Relapse occurred in 27 patients (27.8%), 12 of them (44.4%) being within the fi rst 12 months of the initial diagnosis, and the latest -in their 6 th year. Distributed by location, the majority -23 were bone marrow (BM), and 4 -combined (BM/breast-1; BM/skin-2; BM/CNS/orbit). Relapse rates, within the risk groups, were as follows: 63% in the HR group, 7% in the SR and 30% in the group with no risk assignment. Eight of the relapsed patients were transplanted with hematopoietic stem cells after achieving a second remission (CR2) induced by Although every centre has its own archive, the lack of universal specialized and regularly updated childhood cancer register in Bulgaria is an obstacle that we faced during data collection and we realize that more efforts should be made in establishing and maintaining such a database. The medications used in the treatment of AML have not changed signifi cantly since the 1980s, suggesting that on a global scale current improvement is largely due to: (a) optimization in treatment strategies; (b) establishment of specifi c risk factors and better stratifi cation of patients; (c) meticulous supportive care; (d) use of allogeneic HSCT in HR patients. 10 However some of the most important chemotherapeutics used in the AML-BFM backbone today are still not licensed for the treatment of children and adolescents in Europe and are currently being used on an off-label basis. 13 The OS and EFS rates of children with AML we report are largely due to the use of a unifi ed treatment strategy, using a single treatment protocol. In all of the 3 Bulgarian pediatric oncohematology centers standardized risk group assignment is applied, with timely HLA-typing and referral for transplantation for the HR patients. However, we still do not have unobstructed access to such medications as liposomal daunorubicin, proven to cause less treatment-related toxicity and to be more active against certain types of AML 17, 18 , because of their legal registration regimen and pricing policy.
The prognosis of children with relapsed or primary refractory AML is still unfavorable. The thirteen-year EFS and OS achieved, are currently comparable to those of leading European centers (Table 3) . These results are based on data from the three institutional record offi ces. Yet, a certain duration of CR1 has been found to be the most important prognostic factor in these patients, with little add-on from the other risk factors (cytogenetic, site of relapse, etc.). About 50% of the relapses are early (within 1 year of initial diagnosis) and the prognosis for these patients is poor. 8, 19 Unfortunately, about half of the relapses of our patients fall into this particular group. The exact reasons for relapse are not fully established. Available data suggests that the persistence of minimal residual disease (MRD) might have prognostic signifi cance. 20 For MRD monitoring, highly sensitive techniques are recommended, such as multiparameter fl ow cytometry (FCM) and real time quantitative polymerase chain reaction (RQ PCR). Importantly, the kinetics of relapse differs between genetic subtypes with a median time from molecular to clinical relapse between 2 to 8 months 21 , but more clinical studies are needed in order to determine the exact role of these methods in the monitoring and treatment of children with AML [22] [23] [24] . Currently routine MRD monitoring in children with AML in Bulgaria is available by RQ PCR and FCM, and these studies are becoming increasingly incorporated in the risk stratifi cation of our patients. Unfortunately none of our treatment centers has participated in a large international pediatric AML clinical trial so far.
Second remission could be induced in approximately half of the children with relapsed AML and 20% to 40% of them could be long-term survivors with chemotherapy and HSCT. 8, 25 Cytostatic regimens include FLAG, IDA-FLAG or DNX-FLAG. The latter includes lyposomal daunorubicin (DNX) to reduce cardio toxicity, while maintaining high antileukemic effi ciency. 8, 17, 18 In our cases FLAG and IDA-FLAG are used as a second-line treatment. Stable remission after 2x FLAG, without HSCT is achieved in only 3 cases, and 8 of the others are transplanted in CR2. Unfortunately, there is scarce data in the subsequent medical records regarding CR2 and its duration for most of rest of the relapsed children. This recalls the questions about the national pediatric cancer register.
HSCT has long been used to achieve stable remission in children with relapsed AML. However, the role of allogeneic HSCT in CR1 has recently been revised and today it is reserved only for children with HR AML. [26] [27] [28] [29] [30] [31] [32] For relapsed patients, HSCT in CR2 is the standard, and autologous HSCT is generally not recommended. 33, 34 In our group autologous HSCT was performed in two children at an early period (before 2005) when data about auto-HSCT were controversial, and both of them relapsed. Allogeneic HSCT is utilized in less than one third of all relapsed children. Possible explanations for the low HSCT rates in the period include failure to achieve CR2 and lack of compatible family donors (small families), necessitating the search of MUD, often abroad. This is a time-consuming process involving great human and fi nancial resources and not always successful in short term in a country with limited resources like Bulgaria. Although the fi rst Bulgarian pediatric transplantation center operates since 1997 and is well experienced, no national donor registry has existed until recently, and it has just started to develop. Many reasons contribute: legal, ethical, moral, last but not the least -fi nancial. Transplantation is a proven reserve for improving the survival rates, quality of life and a defi nitive cure for children with relapsed AML. Therefore the question of donation as a prerequisite for a greater share of HSCT in children with hematological malignancies in Bulgaria, remains open.
CONCLUSIONS
Children with newly diagnosed AML in Bulgaria can achieve EFS and OS rates, comparable with those reported by other European groups. Nevertheless, to further increase our OS, a decline in the rates of early death and death in CR1 is needed. Subgroup-directed therapy can be optimized by a precise dynamic risk stratifi cation, utilizing centralized diagnosis reviewing and contemporary minimal residual disease follow-up, by immunophenotyping, karyotyping, FISH and PCR techniques. Essentially, there is a clear need for more successful attempts to cure our children with relapsed AML, because their prognosis is still unfavorable. Administrative limitations in the legal application of second and 3 rd line drugs, and the insuffi cient local participation in clinical studies with experimental medications (as a less-privileged country) contribute to that and should be judiciously addressed. Additionally, there are clear indications for upfront allogeneic transplantation of PBSC in refractory or relapsed AML, and the early HLA-typing with timely referral to the transplantation centre is of utmost importance.
